Urogen Pharma Ltd (URGN) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP cut its holdings in shares of Urogen Pharma Ltd (NASDAQ:URGN) by 13.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,000 shares of the company’s stock after selling 1,100 shares during the quarter. Two Sigma Advisers LP’s holdings in Urogen Pharma were worth $301,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. purchased a new stake in Urogen Pharma in the 3rd quarter valued at $320,000. Bank of New York Mellon Corp purchased a new stake in Urogen Pharma in the 3rd quarter valued at $421,000. BlackRock Inc. raised its position in Urogen Pharma by 14.3% in the 3rd quarter. BlackRock Inc. now owns 102,619 shares of the company’s stock valued at $4,847,000 after purchasing an additional 12,829 shares during the last quarter. BlueMountain Capital Management LLC raised its position in Urogen Pharma by 78.9% in the 3rd quarter. BlueMountain Capital Management LLC now owns 13,557 shares of the company’s stock valued at $640,000 after purchasing an additional 5,979 shares during the last quarter. Finally, Man Group plc raised its position in Urogen Pharma by 404.2% in the 3rd quarter. Man Group plc now owns 106,548 shares of the company’s stock valued at $5,033,000 after purchasing an additional 85,416 shares during the last quarter. Institutional investors own 69.96% of the company’s stock.

Several analysts recently commented on the stock. Oppenheimer set a $70.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Thursday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Urogen Pharma in a research report on Friday, March 1st. Raymond James set a $57.00 price target on shares of Urogen Pharma and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $63.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $68.40.

URGN stock opened at $37.75 on Wednesday. Urogen Pharma Ltd has a 12 month low of $34.61 and a 12 month high of $69.57. The firm has a market capitalization of $500.29 million, a P/E ratio of -7.86 and a beta of 1.44.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, February 28th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.29) by ($0.17). Urogen Pharma had a negative net margin of 4,296.08% and a negative return on equity of 70.67%. As a group, equities analysts forecast that Urogen Pharma Ltd will post -5.47 earnings per share for the current year.

In other Urogen Pharma news, insider Mark Schoenberg sold 1,991 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.30, for a total transaction of $74,264.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/24/urogen-pharma-ltd-urgn-shares-sold-by-two-sigma-advisers-lp.html.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Coverage Ratio

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma Ltd (NASDAQ:URGN).

Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.